Europe Prosthetic Heart Valve Market Expected to Reach $7.1 Billion by 2033

According to a new report published by Allied Market Research, titled, “Europe prosthetic heart valve market size" was valued at $2.5 billion in 2023, and is projected to reach $7.1 billion by 2033, growing at a CAGR of 11.1% from 2024 to 2033. Prosthetic heart valves are used to replace damaged or malfunctioning native heart valves. They are designed to maintain unidirectional blood flow through the heart, mimicking the function of natural valves. These valves are broadly classified into two categories: mechanical valves made from synthetic materials, and bioprosthetic valves from animal or human tissue. The choice of valve depends on factors such as the patient's life expectancy and ability to tolerate anticoagulation therapy.

Europe prosthetic heart valve market growth primarily driven by a significant increase in the prevalence of cardiovascular diseases, particularly valvular heart diseases, has led to a heightened demand for heart valve replacements. For instance, an article published by European Society of Cardiology in 2020, the prevalence of severe aortic stenosis in those aged ≥75 years was 3.4% in Europe and the U.S. In addition, aging population in Europe, which is more susceptible to heart conditions, further drives the demand for treatment options, as older adults often require surgical interventions to address valve dysfunction. Moreover, advancements in medical technology have facilitated the development of innovative prosthetic heart valves, including transcatheter options that offer less invasive procedures, thereby drives the growth during Europe prosthetic heart valve market forecast period.

Furthermore, Europe prosthetic heart valve market trends include robust pipeline of new product approvals and technological innovations, which continue to improve the safety and efficacy of heart valve surgeries. However, challenges such as high costs associated with advanced valve technologies and a shortage of skilled healthcare professionals can impede market growth. On the other hand, investment in R&D activities is another critical opportunity, as companies focus on creating bioengineered solutions that improve valve durability and functionality. This innovation is essential as the market shifts towards more advanced and patient-specific solutions.

Industry Trends 

• According to National Health Service (NHS) UK, the NHS Long Term Plan identifies cardiovascular disease (CVD) as a clinical priority and the single biggest condition where lives can be saved by the NHS over the next 10 years. The Plan sets the ambition for the NHS to help prevent over 150, 000 heart attacks, strokes and dementia cases by 2029. This strategic emphasis on CVD prevention and management promotes investment in cutting-edge valve technologies and enhances the integration of prosthetic valves into treatment protocol thereby supporting the Europe prosthetic heart valve industry. 
• According to European Society of Cardiology, the Valve for Life Initiative, led by the European Association of Percutaneous Cardiovascular Interventions (EAPCI) , aims to enhance access to transcatheter valve interventions (TAVI) in Europe, which is launched in 2015, and it focuses on raising awareness, reducing barriers, and improving education about heart valve therapies. Initially targeting four countries—Poland, France, Portugal, and the UK the initiative seeks to address disparities in access and promote best practices in treating valvular heart disease. In addition, the UK joined the initiative in January 2020 and was selected as the fourth Valve for Life Pilot Country. This growth aligns with the expanding need for advanced heart valve therapies. 

Segment Highlights 

The Europe prosthetic heart valve market size is segmented on the basis of product and country. On the basis of the product, the market is categorized into mechanical heart valve, tissue heart valve, and transcatheter heart valve. The tissue heart valve segment is further classified into stented tissue heart valve and stent less tissue heart valve. The transcatheter segment dominated the Europe prosthetic heart valve market share in 2023 and is expected to remain dominant during forecast period owing to rise in prevalence of heart valve diseases, especially among the aging population the transcatheter heart valves are increasingly preferred for patients with severe aortic stenosis and other valve disorders. On the basis of country the market is classified into Germany, France, UK, Italy, Spain, and Rest of Europe.

Bracco, Edwards Lifesciences Corporation, Medtronic, Boston Scientific Corporation, Abbott Laboratories, Artivion, Inc, Meril Life Sciences Pvt. Ltd., ShockWave Medical, Inc., Novostia SA, and JenaValve Technology, Inc. are the key players operating in the Europe prosthetic heart valve industry. These key players adopt strategies such as product approval, agreement and others to expand the portfolio. For instance, in May 2021, P+F Products + Features GmbH announced that it achieved the CE Mark for its medical device, the TricValve Transcatheter Bicaval Valves System. It is the first bicaval transcatheter valve system worldwide that has been accredited with the CE Mark.